Compare Abbott Laboratories (ABT) vs Aterian Inc (ATER) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Aterian Inc — how do they compare? Abbott Laboratories trades at $95.39 (market cap $166.94B), while Aterian Inc trades at $1.22 (market cap $13.25M). The key difference: Abbott Laboratories is far larger — about 12599.2× Aterian Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Aterian Inc pays none. Which is the better fit depends on your goals.
| ABT | ATER | |
|---|---|---|
Market Cap | $166.94B | $13.25M |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $1.55 |
52-Week Low | $82.57 | $0.54 |
Enterprise Value | $193.69B | $13.83M |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Aterian (ATER) trades at $1.24, down 3.12% today, with a bullish technical signal from moving averages. The company shows improving operational trends with three consecutive quarterly earnings beats, though it remains unprofitable with a -30.78% net margin. Recent news highlights a special stockholders meeting on July 10, 2026, to vote on proposals that could return $0.85–$1.14 per share.
Investment outlook is mixed: positive technical momentum and potential shareholder returns contrast with persistent losses and negative cash flow. Key risks include sustained unprofitability and high short interest growth of 57.7% in March 2026. Analysts are evenly split between Buy and Hold ratings, reflecting cautious optimism amid fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Aterian Inc
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products, and consumer electronics. It has various owned and operated brands include Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. The company generates revenue through the online sales of various consumer products that are sold online.
Read more on ATER →
